Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 351 - 375 of 14564 in total

Mequinol

Mequinol is a phenol used in various applications. It is used as an inhibitor for acrylic monomers and acrylonitirles, as a stabilizer for chlorinated hydrocarbons and ethyl cellulose, as an ultraviolet inhibitor, as a chemical intermediate in the manufacture of antioxidants, pharmaceuticals, plasticizers, and dyestuffs . It is found as...
Approved
Matched Description: … and ethyl cellulose, as an ultraviolet inhibitor, as a chemical intermediate in the manufacture of antioxidants ... Mequinol is a phenol used in various applications. ... It is found as an active ingredient in topical drugs used for skin depigmentation indicated for the treatment …
Matched Categories: … Compounds used in a research, industrial, or household setting …

Metamizole

Metamizole (dipyrone) is a pyrazolone derivative that belongs to the group of nonacid nonopioids. It is considered a potent analgesic and antipyretic with favourable gastrointestinal tolerability. Metamizole was formerly marketed in the US as Dimethone tablets and injection, Protemp oral liquid, and other drug products, and was withdrawn due to...
Approved
Investigational
Withdrawn
Matched Description: … Register of June 17, 1977, 42 FR 30893). ... Metamizole (dipyrone) is a pyrazolone derivative that belongs to the group of nonacid nonopioids. ... [L42975] In 1963, metamizole was withdrawn from the Canadian market and banned in the UK, France, Sweden …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Products: … SEBON 1 G AMPUL, 5 ADET ... SEBON 1 G AMPUL, 10 ADET ... NOGESIC 2 ML 1 GR 10 AMPUL …

Entrectinib

Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. Entrectinib's...
Approved
Investigational
Matched Synonyms: … N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide …
Matched Iupac: … N-{5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl}-4-(4-methylpiperazin-1-yl)-2-[(oxan-4-yl)amino]benzamide …
Matched Description: … [L8081] It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic ... [L8207] Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval ... non-small cell lung cancer and NTRK gene fusion positive solid tumors. …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …

Canagliflozin

Canagliflozin, also known as Invokana, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018...
Approved
Matched Description: … It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 ... for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type ... Cardiovascular disease is the most common cause of death in these patients [A177083]. …
Matched Categories: … Drugs Used in Diabetes ... Heterocyclic Compounds, 1-Ring …

Fingolimod

Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was also...
Approved
Investigational
Matched Description: … [A176474] Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting ... It was developed by Novartis and initially approved by the FDA in 2010. ... [L12651] Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with …
Matched Categories: … Sphingosine 1-phosphate Receptor Modulator ... Sphingosine 1 Phosphate Receptor Modulators ... Sphingosine-1-phosphate (S1P) receptor modulators …

Cocoa

Cocoa allergenic extract is used in allergenic testing.
Approved
Matched Description: … Cocoa allergenic extract is used in allergenic testing. …

Ponatinib

Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Approved
Investigational
Matched Iupac: … 3-(2-{imidazo[1,2-b]pyridazin-3-yl}ethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl …
Matched Description: … mutation for the treatment of chronic myeloid leukemia. ... Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I …
Matched Categories: … Heterocyclic Compounds, 1-Ring ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …

Levoleucovorin

Levoleucovorin is the enantiomerically active form of Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin). Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro, the levo-isomer has been shown to be...
Approved
Investigational
Matched Description: … Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary ... This results in a deficiency of coenzymes and a resultant buildup of toxic substances that are responsible ... However, in order to function in this role, it must first be reduced by the enzyme dihydrofolate reductase …
Matched Categories: … Compounds used in a research, industrial, or household setting …

Cefadroxil

Long-acting, broad-spectrum, water-soluble, cephalexin derivative.
Approved
Vet approved
Withdrawn
Matched Iupac: … (6R,7R)-7-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2- …
Matched Products: … CEFADROXILO 250MG/5ML POLVO PARA RECONSTITUIR A SUSPENSIÓN ORAL ... CEFADROXILO 1 G ... FADROX 1 G TABLETAS …

Flibanserin

Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder...
Approved
Investigational
Matched Iupac: … 1-(2-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}ethyl)-2,3-dihydro-1H-1,3-benzodiazol-2-one …
Matched Description: … of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout Pharmaceuticals ... women by the FDA in August 2015. ... displaying agonist activity on 5-HTA1 and antagonist on 5-HTA2, resulting in lowering of serotonin in …
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …

Mosunetuzumab

Mosunetuzumab is a humanized anti-CD20/CD3 bispecific antibody. It can recognize and bind two different targets simultaneously, CD20 on cancer B-cells and CD3 on T-cells, allowing it to redirect T-cell cytotoxic activity to cancer cells. The standard of care for patients with B-cell lymphoma includes an anti-CD20 monoclonal antibody, such as...
Approved
Investigational
Matched Description: … [L42245] In January 2023, the use of mosunetuzumab was approved by the FDA under accelerated approval ... [L42245] In June 2022, the European Medicines Agency approved mosunetuzumab for the treatment of adult ... leukemia (CLL) or aggressive B-cell lymphoma, have a high probability of relapse or recurrence after …

Lumasiran

Lumasiran is a small interfering RNA used in the treatment of primary hyperoxaluria type 1 (PH1). This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of oxalate, causing calcium crystal formation. These patients experience frequent kidney stones, nephrocalcinosis, and renal failure. Oxlumo, producted by...
Approved
Investigational
Matched Description: … Lumasiran is a small interfering RNA used in the treatment of primary hyperoxaluria type 1 (PH1). ... [L23554] This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads ... [L23554] Oxlumo, producted by Alnylam Pharmaceuticals, represents the first approved treatment for …

Doravirine

Doravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) intended to be administered in combination with other antiretroviral medicines.[L12729,L4562] Doravirine is available by itself or as a combination product of doravirine (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg). Doravirine is formally indicated for the treatment of...
Approved
Investigational
Matched Iupac: … 3-chloro-5-({1-[(4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)-1,2 …
Matched Description: … [L4562] Doravirine is formally indicated for the treatment of HIV-1 infection in adult patients with ... [L12729,L4562] Doravirine is available by itself or as a combination product of doravirine (100 mg), ... treatments available for the management of HIV-1 infection. …
Matched Categories: … Antivirals used in combination for the treatment of HIV infections ... Heterocyclic Compounds, 1-Ring ... Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor …

Flortaucipir F-18

Flortaucipir F-18, also known as 18F-T807 and 18F-AV-1451, is a small indole molecule synthesized with a radioactive fluorine isotope. It is used as a marker in positron emission tomography (PET) imaging of patients suspected of having Alzheimer's disease. After crossing the blood-brain barrier, flortaucipir F-18 binds to aggregated tau protein,...
Approved
Investigational
Matched Description: … [A203933] It is used as a marker in positron emission tomography (PET) imaging of patients suspected ... It was approved by the FDA on May 28, 2020, for sale by Avid Radiopharmaceuticals under the name TAUVID ... ™ and is the first FDA-approved molecule for imaging aggregated tau protein in the brain. …
Matched Categories: … Compounds used in a research, industrial, or household setting ... Diagnostic Uses of Chemicals ... Heterocyclic Compounds, 1-Ring …

Fluticasone furoate

Fluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications[FDA Label] . Fluticasone furoate was first approved in 2007 .
Approved
Matched Iupac: … ,11a-trimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl furan ... (1R,2R,3aS,3bS,5S,9aS,9bR,10S,11aS)-5,9b-difluoro-1-{[(fluoromethyl)sulfanyl]carbonyl}-10-hydroxy-2,9a …
Matched Description: … Fluticasone furoate was first approved in 2007[L5965]. ... Fluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various …

Acarbose

Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are responsible for the metabolism of complex starches and...
Approved
Investigational
Matched Iupac: … ,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1- …
Matched Description: … [L31633,A37868] By inhibiting the activity of these enzymes, acarbose limits the absorption of dietary ... Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the ... breakdown of complex carbohydrates in the intestines. …
Matched Categories: … Drugs Used in Diabetes …

Fluoxymesterone

An anabolic steroid that has been used in the treatment of male hypogonadism, delayed puberty in males, and in the treatment of breast neoplasms in women.
Approved
Illicit
Matched Iupac: … 9b-fluoro-1,10-dihydroxy-1,9a,11a-trimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a] …
Matched Description: … , and in the treatment of breast neoplasms in women. ... An anabolic steroid that has been used in the treatment of male hypogonadism, delayed puberty in males …
Matched Categories: … Sex Hormones and Modulators of the Genital System …

Enzacamene

Commonly known as 4-methylbenzylidene-camphor (4-MBC), enzacamene is a camphor derivative and an organic chemical UV-B filter. It is used in cosmetic products such as sunscreen to provide skin protection against UV rays. While its effects on the human reproductive system as an endocrine disruptor are being investigated, its use in...
Approved
Matched Description: … its use in over-the-counter and cosmetic products is approved by Health Canada. ... Commonly known as 4-methylbenzylidene-camphor (4-MBC), enzacamene is a camphor derivative and an organic ... It is used in cosmetic products such as sunscreen to provide skin protection against UV rays. …
Matched Mixtures name: … Outback 2-in-1 Insect Repellent and Protective Sunscreen …

Lisocabtagene maraleucel

Lisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to brexucabtagene autoleucel and axicabtagene ciloleucel.[A228493,L31588] Lisocabtagene maraleucel is a genetically modified autologous T-cell therapy that targets CD19, the B-lymphocyte surface antigen B4. CAR T-cell therapy has changed the treatment of B-cell lymphomas, significantly increasing survival rates over standard...
Approved
Matched Description: … an overall increase in quality of life over a 1 year period. ... [A228493] However, data on the efficacy of CAR T-cell therapies on less severe forms of B-cell lymphoma ... [A228493] Despite the adverse reactions, the majority of patients given lisocabtagene maraleucel reported …
Matched Categories: … Antineoplastic cell and gene therapy …

Ingenol mebutate

Ingenol mebutate was approved by the FDA in January 2012, and it is marketed under the name Picato®. Picato gel is indicated for the topical treatment of actinic keratosis. Before approval, ingenol mebutate was called PEP005 as an investigational drug. PEP005 is a selective small molecule activator of protein kinase...
Approved
Matched Description: … Ingenol mebutate was approved by the FDA in January 2012, and it is marketed under the name Picato®. ... peplus, whose sap has been used as a traditional medicine for the treatment of skin conditions including ... PEP005 is a selective small molecule activator of protein kinase C (PKC) extracted from the plant Euphorbia …

Nelfinavir

Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
Approved
Matched Description: … Nelfinavir is a potent HIV-1 protease inhibitor. ... It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children ... , resulting in noninfectious, immature viral particles. …

Alipogene tiparvovec

Alipogene tiparvovec is an adeno-associated viral vector of serotype 1-based gene therapy that delivers the Ser(447)X variant of the human lipoprotein lipase (LPL) gene. It is being investigated for the treatment of lipoprotein lipase (LPL) deficiency.[A259796, A259801, A259806, A259811]
Approved
Investigational
Matched Description: … the Ser(447)X variant of the human lipoprotein lipase (LPL) gene. ... Alipogene tiparvovec is an adeno-associated viral vector of serotype 1-based gene therapy that delivers ... It is being investigated for the treatment of lipoprotein lipase (LPL) deficiency. …

Alendronic acid

Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label] .
Approved
Matched Synonyms: … 4-amino-1-hydroxybutane-1,1-diphosphonic acid ... (4-amino-1-hydroxybutylidene)bisphosphonic acid ... (4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonic acid) …
Matched Iupac: … (4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid …
Matched Description: … Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of ... It functions by preventing resorption of bone[FDA Label][A959]. …
Matched Mixtures name: … OSSOFORTIN A 70 MG+1200 MG/800 IU TEDAVİ PAKETİ, 4+24 ADET …
Matched Categories: … Drugs for Treatment of Bone Diseases …

Lanadelumab

Lanadelumab, also known as DX-2930, is a human IgG1 monoclonal antibody designed for subcutaneous self-injection. It is a fully human immunoglobulin, k-light-chain made in recombinant Chinese Hamster Ovary cells. It has been granted priority review, breakthrough therapy, and orphan drug designations for rare diseases based on the results of clinical...
Approved
Investigational
Matched Description: … 2018,[L4537] followed by Health Canada in October 2018[L49226] and the EMA in November 2018. ... [A38676] Lanadelumab was approved for use in patients with hereditary angioedema by the FDA in August ... results of clinical trials. …
Matched Categories: … Drugs Used in Hereditary Angioedema …
Matched Products: … TAKHZYRO 300 MG/2 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET …

Apremilast

Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as Roflumilast and Crisaborole.[A181244,L7495] Initially approved in 2014, it is marketed by Celgene. In July 2019, apremilast was granted...
Approved
Investigational
Matched Synonyms: … N-{2-[(1S)-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4- …
Matched Iupac: … N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl …
Matched Description: … [L7501] In July 2019, apremilast was granted a new FDA approval for the treatment of oral ulcers associated ... of symptoms resulting from certain inflammatory autoimmune diseases. ... [A181244,L7495] Initially approved in 2014, it is marketed by Celgene. …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Displaying drugs 351 - 375 of 14564 in total